Back to search

Peptide record

TPDB41271

myristoyl-CM4 Anticancer standard
36 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB41271
myristoyl-CM4
Anticancer
Cancer-related peptides
CancerPPD 2.0
standard
No
A 36-aa standard natural anticancer peptide sequence curated from CancerPPD 2.0, with an available 3D structural model.
C-terminal: Amidation N-terminal: N-myristoylation
Sequence
GRWKIFKKIEKVGQNIRDGIVKAGPAVAVVGQAATI-NH2
Physicochemical Analysis
C174H293N51O45
CHLMSY
AGIKV
3819.56
11.08
7
2
17
+5
7.01
0.114
108.33
Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour
5500
144.00
4
Residue Composition
number
5
A
2
R
1
N
1
D
0
C
1
E
2
Q
5
G
0
H
5
I
0
L
5
K
0
M
1
F
1
P
0
S
1
T
1
W
0
Y
5
V
Amino Acid Distribution
A: 5 R: 2 N: 1 D: 1 C: 0 E: 1 Q: 2 G: 5 H: 0 I: 5 L: 0 K: 5 M: 0 F: 1 P: 1 S: 0 T: 1 W: 1 Y: 0 V: 5
Chemical Descriptors
36
C174H293N51O45
3819.56
11.08
+5
7.01
0.114
Amidation
L
Linear
N-myristoylation
Antimicrobial
Bombyx mori
Evidence Records 3 records
Evidence 1 Activity

Activity

IC50
IC50 = 6 µM
Anticancer
6 µM

Target

Breast cancer
MCF-7
Breast

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2018

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50 = 4 µM
Anticancer
4 µM

Target

Breast cancer
MDA-MB-231
Breast

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2018
Evidence 3 Activity

Activity

IC50
IC50 = 3 µM
Anticancer
3 µM

Target

Breast cancer
MX-1
Breast

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2018